MNPR vs MUJ Comparison

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.